TDMS Study 05212-03 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
OXAZEPAM
NTP Experiment-Test: 05212-03 Report: PEIRPT05
Study Type: CHRONIC Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
Facility: Battelle Columbus Laboratory
Chemical CAS #: 604-75-1
Lock Date: 02/20/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 3 2 26 35
Moribund Sacrifice 8 7 22 15
Survivors
Terminal Sacrifice 39 41 2
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (60)
Liver (60) (60) (60) (60)
Hepatoblastoma 1 (2%) 8 (13%) 9 (15%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 10 (17%) 4 (7%) 9 (15%) 4 (7%)
Hepatocellular Carcinoma, Multiple 1 (2%) 42 (70%) 50 (83%)
Hepatocellular Adenoma 13 (22%) 17 (28%) 6 (10%) 6 (10%)
Hepatocellular Adenoma, Multiple 13 (22%) 19 (32%) 38 (63%) 40 (67%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Mesentery (3) (3)
Histiocytic Sarcoma 1 (33%)
Teratoma Malignant, Metastatic, Ovary 1 (33%)
Fat, Lipoma 1 (33%)
Pancreas (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (60) (60) (60) (60)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Capsule, Adenoma 1 (2%)
Capsule, Histiocytic Sarcoma 1 (2%)
Pituitary Gland (60) (59) (53) (59)
Pars Distalis, Adenoma 3 (5%) 9 (15%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Follicular Cell, Adenoma 4 (7%) 5 (8%) 6 (10%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (60) (60) (58) (60)
Cystadenoma 1 (2%) 3 (5%) 1 (2%)
Granulosa Cell Tumor Malignant 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 2 (3%)
Teratoma Malignant 1 (2%) 1 (2%)
Follicle, Adenoma 1 (2%) 2 (3%)
Uterus (60) (60) (60) (59)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%)
Cervix, Histiocytic Sarcoma 1 (2%) 1 (2%)
Endometrium, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Lymph Node (3) (2) (1)
Pancreatic, Histiocytic Sarcoma 1 (50%)
Renal, Teratoma Malignant, Metastatic, Ovary 1 (33%)
Thoracic, Histiocytic Sarcoma 1 (50%)
Lymph Node, Bronchial (1)
Lymph Node, Mandibular (58) (57) (58) (54)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (58) (56) (48) (47)
Histiocytic Sarcoma 1 (2%)
Page 3
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Lymph Node, Mediastinal (1) (2) (3)
Histiocytic Sarcoma 1 (50%)
Spleen (60) (60) (60) (59)
Histiocytic Sarcoma 1 (2%)
Thymus (60) (58) (44) (43)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymoma NOS 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (59) (60) (60) (60)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Melanoma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (60) (60) (60) (60)
Diaphragm, Teratoma Malignant, Metastatic,
Ovary 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 3 (5%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 3 (5%) 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatoblastoma, Metastatic, Liver 2 (3%) 2 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (5%) 2 (3%) 8 (13%) 10 (17%)
Histiocytic Sarcoma 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Trachea (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (2) (1)
External Ear, Fibrosarcoma 1 (100%)
Harderian Gland (3) (3) (1) (1)
Adenoma 1 (33%) 3 (100%) 1 (100%) 1 (100%)
Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Histiocytic Sarcoma 2 (3%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Urinary Bladder (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 2 (3%) 1 (2%)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Lymphocytic 2 (3%) 2 (3%) 1 (2%)
Lymphoma Malignant Mixed 1 (2%) 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 45 59 57
Total Primary Neoplasms 63 77 122 118
Total Animals with Benign Neoplasms 31 42 47 48
Total Benign Neoplasms 41 59 55 54
Total Animals with Malignant Neoplasms 19 15 52 54
Total Malignant Neoplasms 21 17 66 64
Total Animals with Metastatic Neoplasms 6 2 8 12
Total Metastatic Neoplasm 12 2 10 12
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 1 1
Total Uncertain Neoplasms 1 1 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 2 4 22 30
Natural Death 3 2 13 20
Survivors
Terminal Sacrifice 45 44 15
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (57) (60) (54) (32)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Colon (59) (60) (60) (59)
Intestine Small, Duodenum (59) (60) (59) (60)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (59) (60) (60) (60)
Carcinoma 1 (2%) 1 (2%)
Liver (59) (60) (60) (60)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatoblastoma 2 (3%) 20 (33%) 13 (22%)
Hepatoblastoma, Multiple 1 (2%) 1 (2%)
Hepatocellular Carcinoma 8 (14%) 4 (7%) 7 (12%) 6 (10%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (3%) 42 (70%) 53 (88%)
Hepatocellular Adenoma 10 (17%) 12 (20%) 7 (12%) 5 (8%)
Hepatocellular Adenoma, Multiple 7 (12%) 9 (15%) 36 (60%) 36 (60%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Kidney 1 (2%)
Mesentery (2) (2) (2) (2)
Histiocytic Sarcoma 1 (50%) 1 (50%)
Fat, Hepatocellular Carcinoma, Metastatic,
Liver 1 (50%)
Pancreas (59) (60) (60) (60)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (60) (59) (60)
Adenoma 1 (2%)
Capsule, Adenoma 6 (10%) 4 (7%)
Capsule, Hepatoblastoma, Metastatic, Liver 1 (2%)
Capsule, Histiocytic Sarcoma 1 (2%)
Adrenal Medulla (59) (60) (60) (60)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (58) (60) (52) (47)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (59) (60) (60) (60)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Prostate (59) (60) (60) (60)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Testes (60) (60) (60) (60)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Lymph Node (2) (1) (1) (2)
Lumbar, Histiocytic Sarcoma 1 (50%)
Popliteal, Histiocytic Sarcoma 1 (100%)
Renal, Hepatoblastoma, Metastatic, Liver 1 (100%)
Lymph Node, Mandibular (54) (54) (52) (52)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (58) (57) (55) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 8
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Sarcoma, Metastatic, Kidney 1 (2%)
Lymph Node, Mediastinal (1) (1)
Histiocytic Sarcoma 1 (100%)
Spleen (59) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (52) (52) (46) (40)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Melanoma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 11 (18%) 12 (20%) 5 (8%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 6 (10%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 7 (12%) 5 (8%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 3 (5%) 10 (17%) 17 (28%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Kidney 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
External Ear, Fibrosarcoma 1 (100%)
Eye (2) (2)
Carcinoma, Metastatic, Harderian Gland 1 (50%) 1 (50%)
Ciliary Body, Adenoma 1 (50%)
Harderian Gland (3) (2) (1)
Adenoma 1 (33%) 1 (50%) 1 (100%)
Carcinoma 1 (33%) 1 (50%)
Bilateral, Adenoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Urinary Bladder (59) (60) (60) (59)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 2 (3%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05212-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/18/94
Route: DOSED FEED Time: 09:53:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 125 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 40 59 60
Total Primary Neoplasms 59 69 125 118
Total Animals with Benign Neoplasms 32 35 46 42
Total Benign Neoplasms 41 48 51 44
Total Animals with Malignant Neoplasms 17 19 51 60
Total Malignant Neoplasms 18 21 73 74
Total Animals with Metastatic Neoplasms 2 4 21 22
Total Metastatic Neoplasm 2 7 27 22
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------